{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.7","value":"2.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Percent of CMV virus binding CD8+ t-cells at day +365 post-transplant","dispersionType":"Standard Error","groups":[{"description":"Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.\n\nAbatacept: Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.","id":"OG000","title":"Abatacept"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Day +365 post-transplant","title":"Protective Immunity","type":"SECONDARY","unitOfMeasure":"percentage of total CD8+ t-cells"}